ABSTRACT
Bacterial colonization of the lungs of CF patients was almost exclusively due to P. aeruginosa. Once chronic colonization occurred, the pseudomonads existed primarily in a nontlagellated mucoid form against which therapeutic treatment was mostly unsuccessful. NABI prepared a polyclonal human hyperimmune IVIG from the plasma of donors immunized with a mucoid exopolysaccharide MEP vaccine developed by Pier. This new hyperimmune IVIG was designed for the prevention and treatment of chronic Pseudomonas infections in CF patients (147) and is currently undergoing evaluation in Phase II trials in both the U.S. and Europe, using a total of 170 patients (137,150).
